Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Not-for-profit research institutions are strong sources and drivers of innovation. And collaborating with universities, research hospitals and foundations is an increasingly important way for companies to accelerate value creation – whether the field is life science, healthcare IT, medical devices or engineering technology.
At Faber, we’ve represented 2,000+ clients in life sciences, healthcare IT, medical devices and engineering technology.
At Faber, our integrated team of lawyers and contracts specialists have helped our clients launch hundreds of clinical trials, and collectively they’ve worked on over 10,000 CTAs.
Increasingly, the collection and exploitation of large data sets, and the leverage of complex software systems (including machine learning, organs-on-a-chip, and laboratory high-throughput automation) are changing pharmaceutical R&D.
Private capital drives the translation of new learnings in basic science to the development of products that meet medical needs. Notwithstanding the proliferation of “industry standard” venture financing documents, crafting the financial and governance terms of a financing to align the interests of scientific founders and investors remains an art.